Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, BooDog, kkpennies, John Kent, NewTrader2017
Search This Board: 
Last Post: 4/20/2018 6:12:49 PM - Followers: 157 - Board type: Free - Posts Today: 0
* shareholders, please consider purchasing product(s)



Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.

FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.

“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.

FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.

FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.

In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.

About FlutiCare™

FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.

FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred

  • #1 form used by patients;
    #1 nasal steroid active prescribed by physicians;
    Familiar to patients, comfort of a known & trusted medicine;
    Engrained in patients’ allergy management; and
    Effective and safe.





Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

  Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Current Report Filing (8-k) 04/06/2018 04:46:59 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/06/2018 04:46:58 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/03/2018 04:35:50 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/03/2018 04:34:55 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/03/2018 04:34:05 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#14493  Sticky Note ((((NEWS OUT)))) April 10, 2018 - 8:54 AM EDT florida investor 04/10/18 02:04:55 PM
#13583  Sticky Note SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with kkpennies 02/14/18 08:30:09 PM
#12430  Sticky Note !!! $INNV Investor Starter Guide !!!! John Kent 11/20/17 10:31:19 AM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#14646   gonna BETS on INNVD too? TrueTrades 04/20/18 06:12:49 PM
#14645   Exactly TRUE! Drugdoctor 04/20/18 05:43:08 PM
#14644   I agree on your comments. I personally hate ShawnP123 04/20/18 05:30:21 PM
#14643   The share price is nothing but a manipulated jtaylor68 04/20/18 02:51:33 PM
#14639   name calling wont help your cause TrueTrades 04/20/18 09:53:12 AM
#14638   the share structure 280/292.5 sucks TrueTrades 04/20/18 09:52:23 AM
#14636   Dr. Da has stated a minimum of two ShawnP123 04/20/18 07:20:30 AM
#14635   Every day we get a red day the Clev3land 04/20/18 06:35:08 AM
#14634   LMAO - now we are talking IF... absolutely Drugdoctor 04/20/18 06:00:37 AM
#14633   no there is no public record but the TrueTrades 04/19/18 08:11:57 PM
#14632   Do you have the link to the vote ShawnP123 04/19/18 07:55:26 PM
#14631   we talked about this last year TrueTrades 04/19/18 06:00:07 PM
#14630   they will run out of operating cash by TrueTrades 04/19/18 05:55:58 PM
#14629   I'm sure feel your shortsightedness will be rewarded ShawnP123 04/19/18 05:48:26 PM
#14628   up to 250,000 innv and 600,000 OVIT. biotech2 04/19/18 04:34:17 PM
#14627   The market is not responding? go ahead take florida investor 04/19/18 04:04:02 PM
#14626   Seems like the market doesn't agree with the ShawnP123 04/19/18 02:55:15 PM
#14625   Good idea Florida Investor, you would think that gi197845 04/19/18 12:00:43 PM
#14624   based on my DD I really think we florida investor 04/19/18 07:48:34 AM
#14623   flordia investor I very much like === what learn/ing 04/18/18 10:33:20 PM
#14622   Your approach makes sense. It's probably the reason jtaylor68 04/18/18 01:06:11 PM
#14621   Fist thing I ask before investing, are they florida investor 04/18/18 11:11:31 AM
#14620   Congrats! You seem to have a nose for jtaylor68 04/18/18 09:21:46 AM
#14619   Yes Sr!!! florida investor 04/18/18 05:39:26 AM
#14618   Sign me up for the Fiji Islands for Batermere 04/17/18 10:56:10 PM
#14617   I want to share with you a true florida investor 04/17/18 10:22:55 PM
#14616   Works for me. The sooner the better. I Batermere 04/17/18 09:13:42 PM
#14615   Dont need a year. We will be over jbdiver 04/17/18 09:06:18 PM
#14614   its already been 2 bat TrueTrades 04/17/18 05:51:51 PM
#14613   Blah blah blah. Get back to me in Batermere 04/17/18 05:41:08 PM
#14611   I'm not sure what that catalyst would be, Batermere 04/17/18 04:33:58 PM
#14610   Im afraid thats what its going to take. jbdiver 04/17/18 02:33:42 PM
#14609   Fluticare is a generic of Flonase and so ShawnP123 04/17/18 02:25:06 PM
#14608   No kidding. We need a catalyst to get Batermere 04/17/18 12:17:05 PM
#14607   volume drying jbdiver 04/17/18 12:10:36 PM
#14606   True, but as you said that's for people florida investor 04/17/18 10:47:02 AM
#14605   I get their press releases to my email. kkpennies 04/17/18 10:11:48 AM
#14604   I indeed am a mod. of the board, Drugdoctor 04/17/18 10:06:40 AM
#14603   Good morning DrugDoctor, I see that you are florida investor 04/17/18 10:03:29 AM
#14601   I said MOSTLY jtaylor68 04/17/18 03:51:55 AM
#14600   Ok, that is a good point. I'm sort gi197845 04/16/18 10:47:02 PM
#14599   competition is part of the business, and let florida investor 04/16/18 07:39:31 PM
#14598   Costco, Kirkland brand fluti is sold on Amazon, gi197845 04/16/18 07:01:49 PM
#14597   It's Costco's private label store brand mostly sold jtaylor68 04/16/18 04:36:57 PM
#14596   Let's see if we can get this SP Batermere 04/16/18 12:27:09 AM
#14595   Costco's fluticasone is considered a generic product, florida investor 04/15/18 09:32:22 PM
#14593   Yes, Shaw don’t forget that Fluticare, it is DrPT 04/15/18 07:58:00 PM
#14592   You can take this to the bank. This DrPT 04/15/18 07:54:47 PM
#14591   I'm glad Innovus is expanding sales and marketing gi197845 04/15/18 07:12:46 PM
#14590   I've said this before, but Innovus would have gi197845 04/15/18 07:08:05 PM